Based on the SMS Pharmaceuticals Limited stock forecast from 0 analysts, the average analyst target price for SMS Pharmaceuticals Limited is not available over the next 12 months. SMS Pharmaceuticals Limited’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of SMS Pharmaceuticals Limited is Slightly Bearish, which is based on 6 positive signals and 12 negative signals. At the last closing, SMS Pharmaceuticals Limited’s stock price was INR 214.20. SMS Pharmaceuticals Limited’s stock price has changed by +5.73% over the past week, +17.15% over the past month and +164.44% over the last year.
No recent analyst target price found for SMS Pharmaceuticals Limited
No recent average analyst rating found for SMS Pharmaceuticals Limited
Company Overview SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers anti-ulcer, anti-fungal, anti-migraine, anti-diabetic, anti-epileptic, anti-psychotic, anti-inflammatory, anti-fungal, anti-viral, anti-coagulant, and anti-retroviral products. It is also involved in the contract research activities. The company also exports its products. SMS Pharmaceuticals Limited was incorporated in 1987 and is based in Hyderabad, India. Read Less
SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers anti-ulcer, anti-fungal, anti-migraine, anti-diabetic, anti-epileptic, anti-psychotic, anti-inflammatory, anti-fungal, anti-viral, anti-coagu...Read More
Frequently Asked Questions About SMS Pharmaceuticals Limited (SMSPHARMA:NSE) Stock
Stock Target Advisor's fundamental analysis for SMS Pharmaceuticals Limited's stock is Slightly Bearish.
SMSPHARMA:NSE stock's dividend yield is 0.17%.
Our analysis grades SMSPHARMA:NSE stock's dividend yield at F. This means that SMSPHARMA:NSE stock's dividend yield is above 20% of the stocks in the Drug Manufacturers - General sector in the NSE exchange.
Based on this SMSPHARMA:NSE may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on SMSPHARMA:NSE's stock to indicate what its average analyst target is.
SMSPHARMA:NSE stock's Price/Earning ratio is 41.74.
Our analysis grades SMSPHARMA:NSE stock's Price / Earning ratio at F. This means that SMSPHARMA:NSE stock's Price/Earning ratio is above 64% of the stocks in the Drug Manufacturers - General sector in the NSE exchange.
Based on this SMSPHARMA:NSE may be a overvalued for its sector.
The last closing price of SMSPHARMA:NSE's stock was INR 214.20.
The most recent market capitalization for SMSPHARMA:NSE is INR 15.09B.
Unfortunately we do not have enough analyst data on SMSPHARMA:NSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains SMS Pharmaceuticals Limited's stock.
As per our most recent records SMS Pharmaceuticals Limited has 1,095 Employees.
SMS Pharmaceuticals Limited's registered address is Plot No. 72, Hyderabad, India, 500034.
You can get more information about it from SMS Pharmaceuticals Limited's website at https://www.smspharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Underpriced on free cash flow basis
The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior Dividend Growth
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
High dividend returns
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
What not to like
Poor capital utilization
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
Poor return on assets
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SMSPHARMA:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
